Illumina to Acquire Grail, a Early Cancer Testing Company, for $8 billion

Illumina will acquire Grail, an Illumina spin-out that is developing an early screening test for multiple forms of cancer, for $8 billion in cash and stock. In 2017, Grail bought Cirina, a Hong Kong-San Francisco liquid biopsy company cofounded by Dr. Dennis Lo, a pioneer in testing blood to detect early stage cancer. Cirina was backed by Decheng Capital (ChinaBio Today® will interview Decheng Capital about the blockbuster deal and publish their comments). Grail expects to launch its first product, GalleriTM, a test for more than 50 types of cancer, in 2021. More details.... Stock Symbol: (NSDQ: ILMN) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.